Success-Driven Molecular Discovery
Screen trillions of compounds.
Only pay for hits.
More than a dozen biotechs trust OpenBench to launch their small molecule drug discovery campaigns.
Launch your next discovery campaign with OpenBench.
Trusted by
Discover high quality start-of-chemistry faster than ever
Conventional fee-for-service hit discovery is filled with uncertainty: high up-front costs, opaque, commodity-grade screens on protracted timelines, and dubious claims about technical capabilities.
OpenBench cuts through the noise to deliver success-driven hit discovery. You define the target hit profile before launching a discovery collaboration. You receive experimental data in weeks, not months. Most importantly, you only pay for hit series that meet your standards.
Early discovery for the modern biotech
OpenBench complements modern biotech business and R&D models.
Not fee-for-service, fee-for-success
The first dollar you spend with OpenBench is to purchase potent, developable chemical matter.
Succeed fast, fail faster
OpenBench delivers targeted, enriched compound libraries to your labs less than two months from launch. Early stopping criteria give you options to exit unsuccessful projects early at no cost to you.
Transparent pricing
Know exactly how much you will pay before you launch a collaboration.
Work with your assays and preferred CROs
The best data is generated in your hands. No transfer of assays necessary.
No royalties or milestones
OpenBench collaborators purchase IP outright upon completion of a project–incurring no continuing obligation to pay milestones or royalties.
Attentive, lightweight collaboration model
Asynchronous communication and monthly executive summaries minimize wasteful meetings that distract from your day-to-day research focus.
Protect your competitive interests
OpenBench doesn’t have a pipeline. We grant ten year standard exclusivity on purchased compounds and up to five years of flexible exclusivity on disease targets.
Zero technical friction
The OpenBench virtual screening platform abstracts away the engineering resources and computational infrastructure needed to exploit multi-trillion compound space. You are free to focus on your core science.
Our hit series are potent, novel, and developable
We pride ourselves on delivering high quality hit series that promote rapid optimization. Screening chemical space at unprecedented scale allows us to find potent compounds that are distinct from prior art, have appealing physicochemical properties, and contain readily accessible points of synthetic diversification.
You define success
You know best what hit profile will motivate start-of-chemistry, and we work to meet that profile.
Purchase robust hit series, not fragile singletons
Standard success criteria includes demonstration of initial SAR and confirmation of activity from powder in multiple, orthogonal assay systems.
Hits come medicinal chemist approved
An independent medicinal chemistry assessor removes unfavorable compounds and ensures achievement of success criteria prior to purchase.
Technical superiority drives the success-driven model
OpenBench’s success-driven promise is built on our AI-enabled structure-based virtual screening platform. We have succeeded in finding quality, progressible chemical series for 90% of commercial projects we have completed to-date.
Drugging first-in-class targets
More than 50% of the binding sites we take on have no specific small molecule prior art.
Better data, better algorithms
Exclusive access to high quality experimental datasets helps us achieve algorithmic superiority and unlock tricky targets.
Binding exosites and allosteric sites
Our technology enables the pursuit of conventionally challenging sites. Half of our projects prosecute allosteric sites or non-functional binding sites.
A target and a primary assay are all you need to get started
OpenBench’s discovery technology is structure-based: we require a predicted or experimental target structure to launch a collaboration. We also require at least one validated primary assay, enabled at medium throughput, to confirm specific engagement of your target.
One week, free feasibility assessment
In just one week, we will assess your binding hypothesis and determine if it is well suited to the OpenBench technology. We won’t waste your time and our money on targets that are not a good fit.
Extending structural enablement
We can deploy homology, MD, and AlphaFold2 based modeling on your behalf to enable structure-based virtual screens for targets that lack a crystal structure.
Developing confirmatory assays
We can help you construct robust models of target engagement that govern the success of a project.
What Our Collaborators Say
“Our collaboration with the team at OpenBench has been both innovative and productive, providing hits for one of our early drug discovery programs by leveraging the cutting edge OpenBench AI methodologies. Their computational AI approach has been complementary to traditional screening approaches to find robust entry points for our medicinal chemistry team.”
Brian Johns, Ph.D.
(then) CSO at HemoShear Therapeutics
“It has been great working with you and your team. I’m very impressed with everything you’ve been able to accomplish in 8 months especially since I have had multiple attempts over several years on the same target. It really shows the power of your platform and strength of your team. I hope we can collaborate in the near future!”
Principal Scientist, Medicinal Chemistry
“A terrific virtual screening company.”
SVP, Small Molecule Drug Discovery